Sickle Cell Anemia Treatment in India

Sickle cell anemia treatment in India depends on the severity and type of sickle cell disease. Sickle cell anemia is a lifelong inherited blood disorder that can cause chronic anaemia, severe pain episodes, infections, stroke, organ damage and other complications. Modern treatment can substantially reduce complications. For selected patients with severe disease, hematopoietic stem cell transplantation (HSCT) can offer a potentially curative treatment.

There is no single GAF sickle-cell cost sheet. Hydroxyurea, pain-crisis care, transfusion and chelation are recurring hospital products, not a nationwide package. Named partner planning for bone marrow transplantation is $25,000–$70,000, typically 4–8 weeks in or near the unit. Neighbouring allogeneic stem cell transplant is $30,000–$80,000 (typically 6–10 weeks nearby). Neighbouring haploidentical stem cell transplant is $35,000–$85,000. Neighbouring matched unrelated donor transplant is $40,000–$95,000. Neighbouring pediatric bone marrow transplantation is $28,000–$75,000. Neighbouring matched sibling donor transplant is $28,000–$70,000. Neighbouring hematopoietic stem cell transplantation is $24,000–$70,000. Neighbouring bone marrow biopsy is $300–$900 (day-care). Neighbouring precision oncology is $2,000–$7,000 when an NGS panel plus clinic visit is the named product — it is not a substitute HPLC or carrier-screen package. Comparable US BMT planning is $150,000–$400,000; allogeneic is $200,000–$420,000. These are planning ranges from partner hospital cost sheets, not hospital quotations. There is no live GAF gene-therapy, hydroxyurea or transfusion-cycle sheet.

India has specialised haematology centres that manage sickle cell disease with hydroxyurea, transfusion programmes, complication care and selected allogeneic transplantation. The Government of India launched the National Sickle Cell Anaemia Elimination Mission in 2023 and has published screening updates through 2026. That is a public-health programme, not a GAF ranking. The 2026 Indian College of Hematology and Indian Council of Medical Research consensus covers screening, diagnosis, crises, transfusion, iron overload, complications, HSCT, gene therapy, immunisation, pregnancy and monitoring.

International patients comparing haematologists commonly start with city lists in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. When a graft is already on the table, bone-marrow-transplantation lists in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad are the live facet. Allogeneic lists include Delhi NCR allogeneic stem cell transplant. Partner haematology hospitals in Delhi NCR, Mumbai and Bengaluru, and in Chennai and Hyderabad, are a typical first filter. City cost sheets include Delhi NCR bone marrow transplantation and Delhi NCR allogeneic stem cell transplant, with the same live cities for Mumbai, Bengaluru, Chennai and Hyderabad. Kolkata, Vellore, Pune, Ahmedabad and Chandigarh may have haematology services, but they are not live GAF catalog cities on this site.

Medical note: Sickle cell disease is different in every patient. Treatment should be selected by a haematologist based on age, genotype, symptoms, complications, laboratory findings, previous treatment and overall health. Chest pain with fever or breathlessness, sudden weakness or speech change, seizure, or high fever belongs in a local emergency department, not in a WhatsApp message.

Request a sickle-cell records review

Sickle Cell Treatment at a Glance

Factor	What patients should know
Disease family	Inherited haemoglobin disorder, not a single solid tumour
Common genotypes	HbSS, HbSC, HbS/β⁰-thalassemia, HbS/β⁺-thalassemia
Conventional care	Hydroxyurea, selected transfusion, infection prevention — no GAF medicine package
Named BMT sheet	$25,000–$70,000; typically 4–8 weeks in or near the unit
Neighbouring allogeneic HSCT	$30,000–$80,000; typically 6–10 weeks nearby
Neighbouring paediatric BMT	$28,000–$75,000
Neighbouring matched-sibling graft	$28,000–$70,000
Neighbouring gene therapy	No live GAF sheet. Confirm Indian availability with the treating centre
Specialist	Haematologist, with paediatric, transplant, neurology and eye support when needed
Emergency	Acute chest syndrome, stroke signs or high fever belongs in a local emergency department

What Is Sickle Cell Anemia?

Sickle cell anemia is the most severe and commonly recognized form of sickle cell disease. It is an inherited disorder affecting haemoglobin, the protein in red blood cells responsible for carrying oxygen.

Abnormal haemoglobin can cause red blood cells to become rigid and develop a sickle or crescent shape. These cells can break down prematurely, causing anaemia, and can obstruct small blood vessels, reducing blood and oxygen supply to tissues.

This process can result in pain crises, chronic anaemia, fatigue, infections, acute chest syndrome, stroke, kidney problems, eye disease, bone damage, leg ulcers, pulmonary complications, gallstones and liver complications, and pregnancy-related complications. Severity varies considerably from one person to another.

Thalassemia lists sit on Thalassemia Treatment in India. Leukemia lists sit on Leukemia Treatment in India. Lymphoma lists sit on Lymphoma Treatment in India. Those are different blood pathways.

Ask which sickle-cell genotype this is

Sickle Cell Disease vs Sickle Cell Anemia

The terms are sometimes used interchangeably, but they are not exactly the same.

Sickle cell disease refers to a group of inherited disorders involving abnormal haemoglobin. Sickle cell anemia generally refers to the more severe forms, particularly HbSS, although other genotypes such as HbS/β⁰-thalassemia can produce a similar clinical picture.

Other genotypes include HbSS, HbSC, HbS/β⁰-thalassemia, HbS/β⁺-thalassemia and less common combinations. The genotype can influence symptoms, complications, treatment requirements and the suitability of advanced therapies.

Sickle-cell-disease, hydroxyurea, gene-therapy, pain-crisis and stroke-treatment pages are not live on this site. Use this pillar page plus the named modality sheets.

What Causes Sickle Cell Anemia?

Sickle cell disease is caused by inherited changes in the HBB gene, which affects the beta-globin component of haemoglobin. A person develops SCD when they inherit disease-causing haemoglobin variants from their parents.

A person who carries one sickle-cell gene and one usual beta-globin gene may have sickle cell trait rather than sickle cell disease. Trait and disease are different conditions and should not be confused.

Symptoms of Sickle Cell Anemia

Common symptoms include chronic anaemia, fatigue, episodes of severe pain, swelling of hands and feet in children, jaundice, frequent infections, delayed growth or puberty, shortness of breath, bone or joint pain, abdominal pain, vision problems, and persistent or recurrent leg ulcers.

Pain is one of the most common complications. It occurs when sickled cells obstruct blood flow through small vessels.

Sickle Cell Pain Crisis

A vaso-occlusive episode, commonly called a pain crisis, occurs when sickled red cells obstruct circulation and cause tissue ischaemia. Pain can occur in the back, chest, abdomen, arms, legs, hands, feet or joints. Intensity and duration vary.

Management should be individualised rather than based on a single standard pain prescription. Patients with recurrent pain should also be evaluated for disease-modifying treatment and complications rather than relying only on repeated emergency treatment.

Chest pain with fever or breathlessness is not “just a crisis” until acute chest syndrome has been excluded. That assessment belongs in a hospital, not in a WhatsApp thread.

How Is Sickle Cell Anemia Diagnosed?

Diagnosis generally involves clinical assessment plus laboratory testing.

Doctors may recommend a complete blood count, peripheral blood smear, HPLC or haemoglobin electrophoresis, genetic testing when the genotype needs clarification, reticulocyte count, bilirubin and haemolysis tests, and iron studies — particularly in patients receiving repeated transfusions.

Organ assessment may include kidneys, liver, heart, lungs, eyes, brain and bones depending on history. The 2026 ICH-ICMR consensus addresses selecting diagnostic and screening approaches in different Indian healthcare settings.

Neighbouring precision oncology is $2,000–$7,000 only when an NGS panel plus clinic visit is the named product. It is not a substitute HPLC quotation.

Sickle Cell Anemia Treatment Options in India

There is no single treatment that is appropriate for every patient.

Goals usually include reducing pain crises, preventing infections, reducing anaemia and haemolysis-related complications, preventing organ damage, reducing stroke risk, managing existing complications, improving quality of life, and considering potentially curative treatment in appropriate patients.

1. Hydroxyurea

Hydroxyurea is one of the most important disease-modifying medicines used in SCD. It can increase fetal haemoglobin and reduce the tendency of red cells to sickle. It may help reduce pain crises, acute chest syndrome, some transfusion requirements, hospitalisations and other complications.

The medication requires medical supervision and regular blood-count monitoring. There is no live GAF hydroxyurea package sheet.

2. Blood transfusion

Transfusions can be used for severe anaemia, stroke, prevention of recurrent stroke in selected patients, selected acute chest syndrome, preparation for certain high-risk situations and other serious complications.

Repeated transfusions can cause iron overload. There is no live GAF transfusion-cycle sheet. Ask the hospital to price units, leukodepletion and day-care separately.

3. Iron chelation

Repeated transfusions can cause excess iron to accumulate in the liver, heart and endocrine system. Doctors may use iron-chelating medicines when clinically indicated. Monitoring may include ferritin, liver assessment and cardiac iron assessment in selected patients. There is no live GAF chelation-drug sheet.

4. Pain management

Treatment depends on severity and may include hydration when appropriate, non-opioid analgesics, opioid medicines for moderate-to-severe acute pain when clinically required, hospital-based treatment for severe crises and management of the underlying trigger.

5. Infection prevention

People with SCD can be particularly vulnerable to serious infections, especially children. Preventive care can include routine childhood vaccination, pneumococcal and influenza vaccination, other vaccines based on age, antibiotic prophylaxis for selected young children, and prompt assessment of fever.

6. Stroke prevention

Children with sickle cell anemia may undergo transcranial Doppler ultrasound to identify increased stroke risk. CDC recommends annual TCD screening beginning at around age two and continuing through adolescence. Children with increased risk may require specialist-directed preventive treatment, which can include chronic transfusion in appropriate cases.

7. Eye, kidney and acute chest care

Regular ophthalmic examinations can identify retinal disease before significant vision loss. Kidney monitoring may include blood pressure, creatinine, urine testing and urinary albumin. Acute chest syndrome is a medical emergency: chest pain, fever, cough, difficulty breathing or low oxygen requires urgent hospital assessment.

Share HPLC and crisis records

8. Hematopoietic stem cell transplant

For selected patients, allogeneic HSCT can provide a potentially curative treatment by replacing the abnormal blood-forming system with healthy donor stem cells. It is not automatically appropriate for every person with SCD.

The decision requires evaluation of disease severity, age, previous complications, organ function, donor availability, HLA compatibility, transplant risks, previous treatment, fertility considerations and family preferences. The ICH-ICMR 2026 consensus includes dedicated HSCT recommendations for SCD in India.

Transplant evaluation may be considered particularly after previous stroke, significant neurological complications, recurrent acute chest syndrome, frequent severe pain episodes, significant disease despite optimised medical therapy or other serious SCD-related complications.

A fully matched sibling donor has historically been an important option. Alternative-donor transplantation is more complex and requires careful risk-benefit assessment. Autologous transplant is a neighbouring sheet for other diseases. It is not the typical SCD product.

Named transplant lists sit on Bone Marrow Transplant in India. The BMT sheet is $25,000–$70,000. Neighbouring allogeneic is $30,000–$80,000. Neighbouring haploidentical is $35,000–$85,000. Neighbouring matched unrelated-donor is $40,000–$95,000. Neighbouring paediatric BMT is $28,000–$75,000. Neighbouring matched-sibling is $28,000–$70,000.

The pathway usually involves comprehensive evaluation, donor evaluation, conditioning, stem-cell infusion, engraftment, monitoring and long-term follow-up. Potential risks include infections, graft-versus-host disease, organ toxicity, infertility, graft failure, conditioning-related complications and transplant-related mortality.

Request a sickle-cell transplant review

9. Gene therapy

Gene-based therapies modify a patient's own blood-forming stem cells so they can produce red cells with improved resistance to sickling. Internationally, some products have regulatory approval in selected jurisdictions. Availability and regulatory status vary by country.

The 2026 ICH-ICMR consensus includes gene therapy as an area of SCD management and future treatment development in India. Confirm regulatory approval, clinical eligibility, centre availability, trial status, long-term follow-up, total cost, fertility implications and alternatives before presenting gene therapy as an option. There is no live GAF gene-therapy cost sheet. Do not use the BMT or CAR-T sheets as a gene-therapy price.

Request a named-pathway cost estimate

Sickle Cell Anemia Treatment for Children

Children with SCD require specialised long-term monitoring: early diagnosis, vaccination, infection prevention, hydroxyurea when indicated, growth and nutrition, pain management, TCD stroke-risk screening, eye screening at appropriate ages, kidney monitoring, school and psychological support, and genetic counselling for the family.

Children with severe complications may be evaluated for HSCT. Neighbouring pediatric bone marrow transplantation is $28,000–$75,000. Neighbouring matched sibling donor transplant is $28,000–$70,000. Adult floors are not a substitute because a brochure says they treat all ages.

Paediatric doctor lists include Delhi NCR paediatric haematology and Chennai paediatric haematology.

Share a child's reports for a paediatric sickle-cell opinion

Sickle Cell Anemia Treatment During Pregnancy

Pregnancy in women with SCD requires specialist multidisciplinary care. SCD can increase pregnancy-related risk, and pregnancy can alter disease management. The team may include a haematologist, maternal-fetal medicine specialist, obstetrician, anaesthesiologist and neonatal team. The ICH-ICMR consensus specifically addresses pregnancy and surgery.

Lifestyle and Daily Care

Medical treatment is only one part of SCD management. Patients are generally advised to stay adequately hydrated, avoid extreme temperatures where possible, avoid known triggers, take prescribed medicines consistently, maintain vaccinations, attend follow-up, seek prompt care for concerning symptoms, maintain a healthy diet, avoid smoking, discuss travel and high-altitude exposure with the treating physician, and keep physical activity appropriate to individual health.

When Is Sickle Cell Disease an Emergency?

Seek emergency care for severe or rapidly worsening pain, difficulty breathing, chest pain, high fever, sudden weakness or numbness, difficulty speaking, confusion, seizure, severe headache, sudden vision changes, loss of consciousness, severe abdominal symptoms or unusual lethargy.

A sudden neurological deficit may indicate stroke. Chest pain, fever, coughing and difficulty breathing can indicate acute chest syndrome. Fever can be particularly serious in children because infections may progress rapidly.

These situations belong in a local emergency department. Do not wait for a WhatsApp reply.

Sickle Cell Disease Complications

Because sickled cells can obstruct blood flow and break down prematurely, complications may affect multiple organs.

Body system	Possible complications
Blood	Chronic anaemia, haemolysis
Brain	Stroke, silent cerebral injury
Lungs	Acute chest syndrome, pulmonary hypertension
Kidneys	Albuminuria, chronic kidney disease
Eyes	Retinopathy, vision loss
Bones	Avascular necrosis, bone pain
Heart	Cardiopulmonary complications
Liver	Liver complications, iron overload
Skin	Leg ulcers
Immune system	Serious infections
Growth	Delayed growth and puberty

SCD is therefore best managed as a multisystem condition, rather than only as an anaemia problem.

Sickle Cell Treatment Cost in India

There is no single sickle-cell treatment cost in India because treatment is not a single procedure.

A patient on outpatient hydroxyurea has a different pathway from a child on chronic transfusion for stroke prevention, and a different pathway again from an allogeneic transplant.

International patients should ask hospitals to provide a written estimate separating haematology consultation, medicines, transfusion units, iron studies and MRI, TCD, HLA typing, donor evaluation, conditioning, transplant admission, post-transplant medicines and what is excluded if complications occur.

A government operational guideline for haemoglobinopathies has published a planning figure for HSCT. That is not a current GAF or hospital quotation. Named BMT is $25,000–$70,000. Neighbouring allogeneic is $30,000–$80,000.

WhatsApp +91 90443 46292 for an itemised sickle-cell estimate

How to Choose a Sickle Cell Centre in India

There is no single hospital that is best for every sickle-cell patient.

Look for a dedicated haematology team that already treats SCD, paediatric haematology for children, leukodepleted blood, TCD and stroke services, ophthalmology, nephrology, pulmonology, a transplant unit that already performs allogeneic work for haemoglobinopathies when a graft may be needed, infection-control and ICU support, and long-term follow-up.

For a patient being evaluated for HSCT, the transplant team's experience with sickle cell disease specifically can be more relevant than simply choosing a hospital that performs a large number of unrelated transplants.

Live GAF city lists currently cover Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Kolkata, Vellore, Pune, Ahmedabad, Kochi, Jaipur, Chandigarh and Lucknow are not live GAF catalog cities on this site.

Catalog haematologists currently tagged to blood-disorder or transplant lists include Dr. Ajay Gupta and Dr. Akash Khandelwal in Delhi NCR; Dr. Akshay Shah and Dr. Muralidaran C in Mumbai; Dr. Govind Eriat and Dr. Neema Bhat in Bengaluru; Dr. M. Gopinathan and Dr. Prabu P in Chennai; and Dr. K. Karuna Kumar and Dr. Narender Kumar Thota in Hyderabad. Neighbouring paediatric lists include Dr. Amita Mahajan in Delhi NCR, Dr. Vipin Khandelwal in Mumbai, Dr. Prerana Nesargi in Bengaluru, Dr. G. Vimal Kumar in Chennai and Dr. Parinitha Reddy Gutha in Hyderabad. A catalog tag is not a volume, outcome or ranking claim.

Catalog hospitals currently affiliated with those tagged lists include Indraprastha Apollo Hospital, BLK-Max Super Speciality Hospital and Medanta - The Medicity in Delhi NCR; Wockhardt Hospital, Mumbai and Gleneagles Hospital, Mumbai; Apollo Hospitals, Bannerghatta Road and Gleneagles Hospitals, Bengaluru; Apollo Hospital, Chennai and MGM Healthcare, Chennai; and Yashoda Hospitals, Secunderabad and KIMS Hospitals, Secunderabad.

Find a sickle-cell specialist in India

WhatsApp +91 90443 46292 to match a haematologist

• Haematology hospitals in Delhi NCR
• Haematology hospitals in Mumbai
• Haematology hospitals in Bengaluru
• Haematology hospitals in Chennai
• Haematology hospitals in Hyderabad

How International Patients Can Get Treatment in India

Useful documents include recent CBC reports, HPLC or electrophoresis, genetic testing if available, transfusion history, hydroxyurea history, hospitalisation records, pain-crisis frequency, stroke history, MRI/MRA, TCD, echocardiography, kidney-function reports, eye reports, ferritin, previous transplant evaluation, current medicines and vaccination records. For children, growth charts help.

Once records are reviewed, the hospital can determine whether the patient needs medical management, a comprehensive SCD assessment, a complication-specific evaluation or a transplant consultation.

Step 1: Send medical records

Share diagnosis, laboratory reports, treatment history and previous complications.

Step 2: Haematologist review

A specialist determines the next investigations.

Step 3: Confirm diagnosis and genotype

The genotype should be clearly established where possible.

Step 4: Evaluate complications

The team assesses brain, kidneys, eyes, lungs, heart, bones and other relevant organs.

Step 5: Develop the treatment plan

The plan may involve medicine, transfusion, complication management or transplant evaluation.

Step 6: Donor assessment

For HSCT candidates, HLA testing and donor evaluation are performed.

Step 7: Treatment and follow-up

Treatment follows the finalised plan. Long-term follow-up remains essential.

Plan a sickle-cell treatment journey

Genetic Counseling

Because SCD is inherited, family members may be offered testing to determine whether they carry a sickle-cell variant. Counselling should be non-directive and provided by an appropriately trained professional.

Can Sickle Cell Anemia Be Cured?

For most patients, medicines such as hydroxyurea control the disease rather than eliminate the underlying genetic cause.

HSCT can potentially provide a cure for appropriately selected patients, but it carries significant risks and is not suitable for everyone. Gene-based therapies are developing, but availability, regulatory status and eligibility differ between countries.

A more useful question is whether this particular patient is a suitable candidate for a potentially curative treatment, and what the risks and benefits are compared with continuing medical therapy.

Frequently Asked Questions About Sickle Cell Treatment in India

Is sickle cell anemia treatable in India?

Yes. India provides medical management for SCD, including disease-modifying therapy, transfusion support, management of complications and hematopoietic stem cell transplantation for selected patients.

What is the best treatment for sickle cell anemia?

There is no single best treatment for every patient. Treatment depends on genotype, age, symptoms, complications, transfusion history, response to medicines and overall health.

Is hydroxyurea used in India?

Yes. Hydroxyurea is an important disease-modifying treatment and is included in India-specific SCD recommendations. There is no live GAF hydroxyurea sheet.

Can sickle cell anemia be cured with a bone marrow transplant?

HSCT can potentially cure SCD in appropriately selected patients. It is a major procedure with potentially serious complications. Transplant lists sit on Bone Marrow Transplant in India.

Does every sickle cell patient need a transplant?

No. Many patients are managed with disease-modifying medicines, preventive care, transfusions when indicated and treatment of complications.

How much does sickle cell treatment cost in India?

There is no single package. Recurring medicines and transfusion are hospital-priced. Named BMT is $25,000–$70,000. Neighbouring allogeneic is $30,000–$80,000. Neighbouring paediatric BMT is $28,000–$75,000.

Can children and adults undergo transplant?

Yes, both can be evaluated. Age, organ damage, disease severity, donor availability and transplant risk decide whether a graft is honest.

What happens if there is no matched sibling?

Alternative-donor transplantation may be considered in selected situations and should be evaluated by an experienced transplant team. Neighbouring MUD is $40,000–$95,000. Neighbouring haploidentical is $35,000–$85,000.

Is sickle cell trait the same as sickle cell disease?

No. They are different genetic conditions with different clinical implications.

Is gene therapy available in India?

Confirm regulatory approval and centre availability with a specialist. There is no live GAF gene-therapy sheet.

Which city in India is best for sickle cell treatment?

There is no single best city. Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad are live GAF catalog cities.

Can international patients get sickle cell treatment in India?

Yes. Medical records can usually be reviewed before travel.

Key Takeaways

• Sickle cell anemia treatment in India has moved beyond simply treating anaemia and pain.
• Modern care focuses on preventing complications, modifying disease course, protecting organs and identifying patients who may benefit from allogeneic HSCT.
• There is no single GAF sickle-cell package. Named BMT is $25,000–$70,000. Neighbouring allogeneic is $30,000–$80,000. Neighbouring paediatric BMT is $28,000–$75,000.
• Gene therapy, hydroxyurea and transfusion cycles have no live GAF sheets.
• Transplant lists sit on Bone Marrow Transplant in India.
• Acute chest syndrome, stroke signs or high fever belongs in a local emergency department.

Share HPLC or electrophoresis, genotype, CBC, transfusion and hydroxyurea history, crisis frequency, TCD or MRI if available, and previous transplant notes before making travel arrangements.

Request a sickle-cell treatment plan

Share records for a sickle-cell review

Message a coordinator on WhatsApp

Request a cost review on WhatsApp

Why GAF Healthcare Can Help International Patients

For an international patient, arranging sickle-cell treatment involves medical-record collection, specialist review, hospital coordination, treatment estimates, appointment scheduling, travel planning, local assistance and follow-up coordination.

GAF Healthcare can help coordinate the process with appropriate hospitals and haematology teams. A medical opinion should always come from the treating haematologist or transplant team. GAF Healthcare's role is to facilitate access and coordination rather than replace the medical team.

Related Treatment and Cost Guides

• Bone Marrow Transplant in India — named BMT sheet $25,000–$70,000
• Thalassemia Treatment in India — related haemoglobinopathy pathway
• Leukemia Treatment in India — different blood-cancer pathway
• Lymphoma Treatment in India — different lymphatic-cancer pathway
• Allogeneic stem cell transplant — $30,000–$80,000
• Haploidentical stem cell transplant — $35,000–$85,000
• Matched unrelated donor transplant — $40,000–$95,000
• Pediatric bone marrow transplantation — $28,000–$75,000
• Matched sibling donor transplant — $28,000–$70,000
• Bone marrow biopsy — $300–$900

Sickle-cell-disease, hydroxyurea, gene-therapy, pain-crisis, acute-chest-syndrome and sickle-cell-stroke treatment pages are not live on this site. Use the named modality sheets rather than an invented disease page. Myeloma lists sit on Multiple Myeloma Treatment in India. Aplastic anemia lists sit on Aplastic Anemia Treatment in India. Autologous transplant lists sit on Autologous Bone Marrow Transplant in India. Fanconi anemia lists sit on Fanconi Anemia Treatment in India.

Hydroxyurea, transfusion, transplant and gene-therapy lists treat different briefs. They are not a substitute sickle-cell package.

Top 10 Medical Sources

1. Indian College of Hematology and ICMR — 2026 SCD consensus — India-specific screening, crises, transfusion, HSCT and monitoring.
2. American Society of Hematology — SCD stem cell transplantation — individualised transplant decisions.
3. National Heart, Lung, and Blood Institute — Sickle cell disease treatment — medical management overview.
4. Press Information Bureau — National Sickle Cell Anaemia Elimination Mission — published government screening updates.
5. CDC — Prevention and treatment of SCD complications — crises, infection and organ complications.
6. CDC — Acute chest syndrome and stroke — emergency complications.
7. CDC — TCD stroke-risk screening — paediatric surveillance.
8. GAF Healthcare bone marrow transplantation — partner USD planning of $25,000–$70,000.
9. GAF Healthcare allogeneic stem cell transplant — partner USD planning of $30,000–$80,000.
10. National Health Mission — haemoglobinopathy operational guidance — published programme context, not a current hospital quotation.

Last reviewed against the cited sources: October 2026.

Medical Disclaimer

This page is intended for general educational purposes and should not replace an examination, diagnosis or individualized medical advice from a qualified haematologist.

Sickle cell treatment is individualized. Suitability, protocol, risks, recovery and expected results vary from patient to patient. Treatment protocols, drug availability and gene-therapy approvals can change.

If you develop chest pain with fever or breathlessness, sudden weakness or speech change, seizure, or high fever, seek urgent medical attention in a local emergency department.